Abstract: Generation of by-product is reduced by producing a triazolylmethyl cycloalkanol derivative by reacting a cycloalkanone derivative and an alkali metal salt of 1,2,4-triazole in the presence of a sulfur ylide at a reaction temperature of higher than 110° C. and 140° C. or lower.

Abstract: The present invention provides improved process for the preparation of Deferasirox of formula (I).

Abstract: A method is provided for the thermal photoswitching of spin-transition compounds from the low-spin state to the high-spin state, including at least one step of exposing the material to a non-polarized laser beam which is at room temperature, and the wavelength of which is in the infrared range and the power of which is 1 mW·cm?2 to 1 W·cm?2. The method may be used for the temporary or permanent marking of materials including particles of at least one spin-transition compound including an iron(II) and triazole ligand compound.

Abstract: This disclosure is related to the field of preparation of certain (substituted phenyl)-triazolyl-(substituted phenyl) molecules, and intermediates related thereto, where said intermediates are useful in the preparation of certain insecticides.

Abstract: The invention in this document is related to the field of preparation of haloalkoxyarylhydrazines and certain intermediates derived therefrom, where said intermediates are useful in the preparation of certain pesticides disclosed in U.S. Pat. No. 8,178,658.

Abstract: The present invention provides improved process for the preparation of Deferasirox of formula (I).

Abstract: The present invention relates to processes for the preparation of deferasirox, an oral iron chelator developed to treat iron overload due to e.g. multiple blood transfusions. The present invention further provides novel deferasirox pseudopolymorphs and a novel amorphous form of deferasirox, processes for their preparation, as well as pharmaceutical compositions comprising same, and use thereof in treating iron overload.

Abstract: The present invention relates to a process for the preparation of 1-phenyl-1,2,4-triazoles by converting phenyl hydrazides to N?-(iminomethyl)-N?-phenylacetyl hydrazides and the further reaction thereof by cyclization to give 1-phenyl-1,2,4-triazoles.

Abstract: The present invention constitutes new 3-triazolylphenyl-substituted sulphide derivatives of the formula (I) in which A1, A2, B0, B1, B2, B3, X, R1, R2 and n are as defined in the description, to their use as acaricides and insecticides for controlling animal pests, and to processes for preparing them.

Abstract: The novel process for iodinating substituted azoles, especially for iodinating substituted 1H-tetrazoles and substituted 1H-triazoles, affords the desired compounds in high purity and with good yield.

Abstract: Anastrozole can be purified by crystallization from an aqueous-based solvent system. The aqueous-based solvent system can contain dilute acid, or an alcohol or both.

Abstract: The present invention relates to the improved process for the preparation of Anastrozole free from the impurities arising due to impure 3,5-bis-(1-cyano-1-methylethyl)benzylbromide (2) and other related impurities resulting from incomplete/over-reaction of 2,2-(5-methyl-1,3-phenylene)-bis(2-methylpropionitrile (I).

Abstract: The invention is directed to processes for purifying the Anastrozole intermediate, 3,5-bis(2-cyanoisopropyl)toluene, processes for producing Anastrozole, processes for preparing Anastrozole pharmaceutical compositions, and Anastrozole and Anastrozole pharmaceutical compositions prepared with the processes of the invention.

Abstract: The present invention provides novel crystalline forms of deferasirox, methods for their production, and methods for conversion of the novel forms to the known crystalline form I.

Abstract: The invention relates to 7-amino triazolopyrimidines of formula (I), in which the substituents have the following meanings: R1, R2 represent hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, naphthyl; or 5-membered or 6-membered heterocyclyl containing one to four nitrogen atoms or one to three nitrogen atoms and one sulfur or oxygen atom; or 5-membered or 6-membered heteroaryl containing one to four nitrogen atoms or one to three nitrogen atoms and one sulfur or oxygen atom, or R1 and R2 can, together with the nitrogen atom, which binds them, form a 5-membered or 6-membered ring containing one to four nitrogen atoms or one to three nitrogen atoms and one sulfur or oxygen atom; R3 represents alkyl, alkenyl, alkynyl, cycloalkyl, phenylalkyl and alkyl halide; whereby R3 and R2 can be unsubstituted or partially or completely substituted according to the description; X represents halogen, cyano, alkoxy, alkyl halide, phenyl or phenyl that is substituted by Ra.

Abstract: N-Heterocyclic derivatives of the formula (I): are described herein, as well as other N-heterocycles, as inhibitors of nitric oxide synthase. Pharmaceutical compositions containing these compounds, methods of using these compounds as inhibitors of nitric oxide synthase and processes for synthesizing these compounds are also described herein.

Abstract: The present application describes nitrogen containing heteroaromatics with ortho-substituted P1's and derivatives thereof of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is N or NH and D is substituted ortho to G on E and may be CH2NH2, which are useful as inhibitors of factor Xa.